Table S3. Identified NICE Technology Appraisal decision factors

Condition
- Condition management
- Effect on QoL
  - Patient
  - Carer
  - Family
- Psychological aspects

Current practice
- Currently available treatments
- Current treatment pathway
- Variation in current practice
- Clinical management
- Treatment impact
- Treatment in current practice
- Level of success of current treatment
- Stigma of expert treatment (i.e. drugs/psychological)
- Treatment service
- Treatment duration
- Uptake

Clinical need
- Clinical need for treatment
- Clinical need for additional treatment
- Clinical need for better practice
  - Improved monitoring
  - Improved dosing
- Clinical need of particular sub group

New treatment (/ technology)
- Treatment safety
- Adverse events
- Treatment duration
- Long term treatment effects
- Treatment effectiveness
- New patient access scheme
- Comparator treatment
  - Comparator validity
- Clinical treatment pathway
- Addition to treatment pathway
- Prescription setting
- Adherence issues
- Adjuvant treatment

Studies
- Study relevance
- Study method
- Study quality
- Statistical significance
- Population group
- Population generalisability
- Generalisability to current practice

Clinical effectiveness
- Treatment effectiveness
- Relative effectiveness / comparisons
- Sub group effectiveness
- Sub group comparison
- Application in current practice
- Relevance to clinical practice
- Evidence / New evidence
  - Evidence reliability
  - Evidence availability
  - Evidence suitability
  - Evidence validity
  - Population generalisability
  - Effect on QoL
  - HRQoL
  - HRQoL measurement/instrument
  - Analysis method
- Additional analysis
  - Post hoc efficacy analysis
  - Post hoc subgroup analysis
  - Manufacturer's post hoc analysis
  - ERG's exploratory analyses
  - Sensitivity analysis
  - Scenario analysis
- Relevance comparison
- Long term effects
- Adverse effects
- Risk of recurrence / relapse
- Patient reported outcomes/ PROM
- Health utility
  - Estimation of utility

Cost effectiveness
- Cost effectiveness analysis
- Manufacturer's economic analyses
- Validity
- ICER
  - Estimated ICER(s)
  - Most appropriate/plausible ICER
- Additional analysis
  - Manufacturer's sensitivity analysis
  - Manufacturer's new cost effectiveness estimates
  - ERG amendments
    - Impact
    - Treatment length in practice
    - Treatment application in practice
- Economic model
  - Key drivers of cost/clinical effectiveness
  - Model face validity
  - Model limitations
  - Model relevance
  - Model suitability
  - Model structure
  - Model time horizon
  - Model input
    - HRQoL
    - Treatment in current practice
    - Treatment duration
    - Sub group effectiveness
    - Treatment effectiveness
    - Long term treatment effects
    - Health utility
    - Adverse events
    - Changes in model input
  - Model outcome
    - Sensitivity to model input
    - Long term outcome prediction
    - Effect on QoL
  - Model corrections
- Comparison scenario
  - Most appropriate comparison scenario
  - Representation of current scenario
  - Limitations
- Risk of recurrence / relapse

Other factors
- Innovation
- Rare condition
- Children
- Lack of recent advances in field
- Equality issues
  - Protected characteristics
- Stigmatisation of condition
- Impact on family
- Uncaptured benefits
  - Health benefits
  - HRQoL
    - Patient
    - Family
  - Benefits to particular population groups
- Displacement of other treatments
- End of Life considerations